Literature DB >> 19403029

[Correlaion between serum Golph2 protein and hepatocellular carcinoma].

Long-yi Tan1, Jie Chen, Hao Wang, Han-qing Ye, Qian Li, Ji-an Gu, Li-qin Han.   

Abstract

OBJECTIVE: To study the correlation between hepatocellular carcinoma (HCC) and serum Golph2 protein.
METHODS: Golph2 gene was cloned by RT-PCR using RNA from WBF44 cell line as template, the point mutations of the cloned sequence were corrected by PCR, then the gene (1206 bp) was cloned into pET-21 plasmid, and the resulted plasmid was transformed into E.coli DH5a. The expression of 6xHis and Golph2 fusion protein was induced by isopropylthio-beta-D-galactoside (IPTG). The expression of fusion protein was detected by SDS-PAGE and Western blot, and was purified by Ni NTA chelating agarose. The rabbit antibody against Golph2 protein was obtained by immunizing 2 rabbits with the purified Golph2 protein. The specificity and titer of the antibody was determined by Western-blot and ELISA respectively. Sandwich ELISA was used to detect the level of serum Golph2 protein.
RESULTS: There were two replacement mutation and 1 deletion mutation in the cloned sequence contrasted to NM177937 in Genbank, including 644(T-->C, L-->P) , 970 (G-->A, V-->I) and 802 G deletion. The sequence was completely reversed by PCR. The sequence of Golph2 gene cloned into expression vector was confirmed by DNA sequencing. SDS-PAGE and Western blot analysis showed that Golph2 protein was expressed in E.coli DH5a. The antiserum could bind to the 52 kD recombinant protein and serum 73 kD protein specifically. The mean A450 value of ELISA for serum Golph2 protein were significantly higher in HCC and other liver diseases than that in control groups. The sensitivity and specificity for HCC were 44.5% and 82.0%, respectively, at the cut off value is more than or equal to 0.40.
CONCLUSION: The polyclonal antibody against Golph2 protein is specific. The level of serum Golph2 is significantly higher in patients with HCC and other liver diseases than that in healthy controls.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19403029

Source DB:  PubMed          Journal:  Zhonghua Gan Zang Bing Za Zhi        ISSN: 1007-3418


  4 in total

Review 1.  Glycosylation and liver cancer.

Authors:  Anand Mehta; Harmin Herrera; Timothy Block
Journal:  Adv Cancer Res       Date:  2015-02-07       Impact factor: 6.242

2.  Interleukin-6 and oncostatin M are elevated in liver disease in conjunction with candidate hepatocellular carcinoma biomarker GP73.

Authors:  Hongyan Liang; Timothy M Block; Mengjun Wang; Bradley Nefsky; Ronald Long; Julie Hafner; Anand S Mehta; Jorge Marrero; Robert Gish; Pamela A Norton
Journal:  Cancer Biomark       Date:  2012       Impact factor: 4.388

Review 3.  Golgi protein 73 versus alpha-fetoprotein as a biomarker for hepatocellular carcinoma: a diagnostic meta-analysis.

Authors:  Ying Zhou; Xin Yin; Jun Ying; Boheng Zhang
Journal:  BMC Cancer       Date:  2012-01-16       Impact factor: 4.430

4.  Serum Golgi protein 73 (GP73) is a diagnostic and prognostic marker of chronic HBV liver disease.

Authors:  Zhengju Xu; Liguan Liu; Xingnan Pan; Kaipeng Wei; Meijuan Wei; Lifei Liu; Huanwen Yang; Qian Liu
Journal:  Medicine (Baltimore)       Date:  2015-03       Impact factor: 1.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.